| Name | Title | Contact Details |
|---|
The Accreditation Council for Graduate Medical Education (ACGME) is a private, non-profit, professional organization responsible for the accreditation of approximately 10,000 residency and fellowship programs and the approximately 800 institutions that sponsor these programs in the United States. Residency and fellowship programs educate approximately 125,000 resident and fellow physicians in 150 specialties and subspecialties. The ACGME`s mission is to improve health care and population health by assessing and advancing the quality of resident physicians` education through accreditation. We imagine a world characterized by: • A structured approach to evaluating the competency of all residents and fellows, • Motivated physician role models leading all graduate medical education programs, • High-quality, supervised, humanistic, clinical educational experience, with customized formative feedback, • Clinical learning environments characterized by excellence in clinical care, safety, and professionalism, • Residents and fellows achieving specialty specific proficiency prior to graduation, • Residents and fellows prepared to become Virtuous Physicians who place the needs and well-being of patients first.
AllerVie Health is a national network of board-certified allergists and immunologists partnering together for the advancement of patient care, serving patients across 12 states in 76 clinic locations. Our providers are committed to establishing the allergy and immunology gold standard, expanding access to best-in-class care, and bringing relief and renewed vitality to the millions of Americans affected annually, many of whom live in underserved communities today. AllerVie is relentlessly dedicated to clinical excellence, creating an improved patient experience, and supporting the development of advanced allergy and immunology-focused therapeutics and treatment options. With AllerVie Health, our patients can feel their best, reclaim their lives, and live in freedom!
Cangene BioPharma is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Marin General Hospital provides primary and secondary levels of care in addition to Marin Cancer Institute and Haynes Cardiovascular Institute.
Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.